Status:
UNKNOWN
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Cancer of Stomach
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to investigate the effect of selective COX-II inhibitor in patients with regionally disseminated stomach cancer treated by palliative resection (so called R1 or R2 gastrec...
Detailed Description
Cyclo-oxygenase (COX) is a family of enzymes regulating the conversion of arachidonic acid to prostaglandins. COX-II is an inducible enzyme, which expresses excessively when there are stimuli such as ...
Eligibility Criteria
Inclusion
- Stomach cancer with peritoneal or lymphatic spread beyond the scope of curative resection
- Palliative resection can be performed
- Normal RFT
Exclusion
- Solid organ metastases
- Poor performance status
- On long-term aspirin or NSAID
- Renal or hepatic dysfunction
- Bleeding disorder
- Hypersensitive to COX-II inhibitors/aspirin/NSAID
- No history of myocardial infarct or stroke
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT00165048
Start Date
October 1 2004
Last Update
December 9 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Combined Gastro-intestinal Cancer Clinic
Hong Kong, China